Drug Use Investigation for REVOLADE (ITP)

Novartis Pharmaceuticals5,797 enrolled

Overview

To investigate safety and efficacy in the actual use of REVOLADE collected from all subjects receiving the drug until data from a specified number of subjects are accumulated to identify factors considered to influence its safety and efficacy. \<Priority investigation item\> Thromboembolism

Study Type

OBSERVATIONAL

Enrollment

5,797

Conditions

Purpura, Thrombocytopaenic, Idiopathic

Interventions

EltrombopagDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects with chronic idiopathic thrombocytopenic purpura Exclusion Criteria: * Not applicable

Outcomes

Primary Outcomes

The number of subjects with any adverse events treated with REVOLADE

Time frame: 1 year

Secondary Outcomes

Appearance of thromboembolism

If thromboembolism is appeared or not in subjects who received REVOLADE will be investigated throughout the study period

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.